Summit Therapeutics Inc. filed a current report on November 4, 2026, to submit the legal opinion of Baker & Hostetler LLP relating to the legality of a common stock issuance connected to a prospectus supplement filed under the company's automatic shelf registration statement.

Key Highlights

  • Filing date: November 4, 2026, as reported by Summit Therapeutics Inc. (NASDAQ:SMMT)
  • Prospectus supplement: The company filed a prospectus supplement to its automatic shelf registration statement on Form S-3, Registration No. 333-296642, according to the filing.
  • Legal opinion: Baker & Hostetler LLP provided the opinion on the legality of the issuance of shares of common stock set forth in the prospectus supplement, filed as Exhibit 5.1.
  • Common stock details: The shares are described as common stock with a par value of $0.01 per share, listed on The Nasdaq Stock Market LLC under the symbol SMMT.
  • Signing officer: The report was signed by Manmeet S. Soni, Chief Operating Officer, Chief Financial Officer, and Director, identified as the Principal Financial Officer.

Summit Therapeutics Submits Baker & Hostetler Opinion in Connection with Shelf Registration Offering

Summit Therapeutics Inc., a Delaware-incorporated biopharmaceutical company headquartered at 601 Brickell Key Drive, Suite 1000, Miami, FL 33131, disclosed on November 4, 2026, that it filed a prospectus supplement to its existing automatic shelf registration statement. The registration statement was originally filed on Form S-3 and carries Registration No. 333-296642 with the Securities and Exchange Commission.

According to the filing, the purpose of this current report is specifically to submit the opinion of Baker & Hostetler LLP regarding the legality of the issuance of shares of common stock described in that prospectus supplement. The legal opinion appears as Exhibit 5.1, with the consent of Baker & Hostetler LLP included within that same exhibit as Exhibit 23.1. The filing noted no written communications under Rule 425, no soliciting material under Rule 14a-12, and no pre-commencement communications under Rules 14d-2(b) or 13e-4(c) were intended by this submission.

The company's common stock carries a par value of $0.01 per share and is registered under Section 12(b) of the Securities Exchange Act of 1934. Summit Therapeutics indicated in the filing that it is not an emerging growth company as defined under Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. The Commission File Number assigned to the registrant is 001-36866, and its IRS Employer Identification Number is 37-1979717.

What Was Disclosed

Summit Therapeutics filed a current report on November 4, 2026, to attach a legal opinion from Baker & Hostetler LLP on the validity of a common stock issuance tied to a prospectus supplement under the company's shelf registration statement, Registration No. 333-296642.